Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
2021 ◽
Vol 64
(2)
◽
pp. 909-924
◽
2019 ◽
Vol 234
(9)
◽
pp. 15472-15486
◽
2017 ◽
Vol 80
(6)
◽
pp. 1063-1072
◽
2008 ◽
2017 ◽
Vol 80
(6)
◽
pp. 1073-1077
◽
2019 ◽
Vol 171
◽
pp. 265-281
◽